Business
InspiraTM Technologies Granted Patent by the Israeli Patent Office for Key Safety Component for the INSPIRATM ART System
RA'ANANA, Israel, Nov. 10, 2022 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"RA'ANANA, Israel, Nov. 10, 2022 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the \"Company\" or \"Inspira Technologies\"), a groundbreaking respiratory support technology company, announced today that the Israeli Patent Office (ILPO) granted a patent for a key safety component of the INSPIRATM ART system.\nThe component is to be located on the patient's neck and is designed to secure a neck cannula from moving or dislodging. Cannula movement can occur during a change of a patient's posture in bed, during physiotherapy treatment, while an awake patient is taken by the medical staff out of bed for a short walk and/or during transportation within and between hospitals.\n\"We believe that the grant of this patent is another validation of our innovation and supports our core mission for the INSPIRA ART system – to reduce the dependency on invasive mechanical ventilation and improve patient safety and outcomes,\" stated Inspira's CEO, Dagi Ben-Noon. \"This patent is part of the Company's portfolio of patents that are at various phases of the filing process and which we expect to see progress to grant status.\"\nThe ILPO is a certified International Searching and Examining Authority (ISA), appointed by the World Intellectual Property Organization (WIPO), and a party to the PCT-PPH Program, an international initiative amongst 30+ national patent offices to promote work-sharing and enable accelerated patent applicant processing. The Company plans to file for patent coverage in additional countries.\nEnhances Usability and Medical Value of INSPIRA ART System\nThe newly patented technology shall be a key component of the INSPIRA ART system, a potential new mode of acute respiratory care under development, designed to minimize the need for invasive mechanical ventilation allowing the patient to remain awake and maintain spontaneous breathing\nThe component will be utilized during INSPIRA ART treatment with awake patients, potentially allowing them to be mobile with reduced risk of cannula movement and subsequent bleeding. The Company believes that such improvement in patient safety and mobilization increases patient benefit and enhances the INSPIRA ART system's usability and comprehensive medical value to both patient and medical staff, which may accelerate market adoption. \nPotential Use For ECMO \...